Compass Pathways' depression drug succeeds late-stage trial
23/06/2025 11:34
June 23 (Reuters) - Compass Pathways CMPS.O said on Monday its experimental psilocybin-based therapy helped significantly reduce symptoms of difficult-to-treat depression in a late-stage study. (Reporting by Mariam Sunny and Christy Santhosh in Bengaluru; Editing by Mrigank Dhaniwala) ((Christy.Santhosh@thomsonreuters.com;))
Recent news on COMPASS Pathways
See all newsCompass Pathways PLC reports results for the quarter ended September 30 - Earnings Summary
Corrected: Compass Pathways Q3 net loss narrows on lower R&D charges
Corrected: BRIEF-COMPASS Pathways Q3 EPS USD -0.31
Psychedelic drug developers fall after Usona submits depressive drug application
Compass Pathways PLC expected to post a loss of 45 cents a share - Earnings Preview